BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
4208513
Number of visits today
243
Number of downloads
3843135
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF. Relationship of Anifrolumab Pharmacokinetics With Efficacy and Safety in Patients With Systemic Lupus Erythematosus. Rheumatology (Oxford) 2021:keab704. [PMID: 34528084 DOI: 10.1093/rheumatology/keab704] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kedia N, Theillac V, Paez-escamilla M, Indermill C, Gallagher DS, Adam R, Qu-knafo AL, Amari F, Bottin C, Chotard G, Caillaux V, Strého M, Sedira N, Héron E, Becherel P, Bodaghi B, Mrejen-uretski S, Sahel A, Saadoun D, Errera M. The full range of ophthalmological clinical manifestations in systemic lupus erythematosus. Front Ophthalmol 2023;2. [DOI: 10.3389/fopht.2022.1055766] [Reference Citation Analysis]
2 Acharya C, Magnusson MO, Vajjah P, Oliver R, Zamacona M. Population Pharmacokinetics and Exposure-Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus Erythematosus. J Clin Pharmacol 2022. [PMID: 36453450 DOI: 10.1002/jcph.2188] [Reference Citation Analysis]
3 Liu Z, Cheng R, Liu Y. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Front Immunol 2022;13:996662. [DOI: 10.3389/fimmu.2022.996662] [Reference Citation Analysis]
4 Gulko HE, Furie R; Division of Rheumatology, Northwell Health, Great Neck, NY, USA, Division of Rheumatology, Northwell Health, Great Neck, NY, USA. Anifrolumab: An Inhibitor of Type I Interferon for the Treatment of Patients with Systemic Lupus Erythematosus. Rheumatology 2022;1:29. [DOI: 10.17925/rmd.2022.1.1.29] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345